whittle-martin_227x227

Martin C. Whittle

Staff Scientist

Ph.D., Pharmacology
University of North Carolina, Chapel Hill, NC

B.S., Biochemistry
University of Puget Sound, Tacoma, WA

mwhittle@fredhutch.org


RESEARCH INTERESTS

My background in chemical biology fuels my current research objectives to define cell signaling mechanisms of PDA pathogenesis.  I work to characterize novel mouse models of PDA and define key regulators of metastasis, proliferation, and drug resistance of tumor cells.

 

PUBLICATIONS

Whittle MC, Hingorani SR. Understanding disease biology and informing the management of pancreas cancer with preclinical model systems. Cancer Journal. 2017 Nov/Dec;23(6):326-332.

Whittle MC, Hingorani SR. Chapter 21: Runx3 and Cell Fate Decisions in Pancreas Cancer. In: RUNX Proteins in Development and Cancer, Advances in Experimental Medicine and Biology 962. Y. Groner et al., eds., Springer Nature Singapore Pte Ltd., 2017. doi: 10.1007/978-981-10-3233-2_21.

Zhong Y, Macgregor-Das AM, Saunders T, Whittle MC, Makohon-Moore A, Kohutek ZA, Poling J, Herbst BT, Javier BM, Cope L, Leach SD, Hingorani SR, Iacobuzio-Donahue CA. Mutant p53 together with TGFβ signaling influence organ-specific hematogenous colonization patterns of pancreatic cancer. Clinical Cancer Research. 2017 Mar 15;23(6):1607-20. PMCID: PMC5354987

Whittle MC, Hingorani SR. Disconnect between EMT and metastasis in pancreas cancer. Oncotarget. 2015 Oct 13;6(31):30445-6. PMCID: PMC4741540

Whittle MC, Hingorani SR. RUNX3 defines disease behavior in pancreatic ductal adenocarcinoma. Mol Cell Oncol. 2015 Jul 29;3(2):e1076588. PMCID: PMC4905377

Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. RUNX3 controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell. 2015 Jun 4;161(6):1345-60. PMCID: PMC4458240

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM. Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One. 2013 Jun 24;8(6):e66755. PMCID: PMC3691232

Graves LM, Duncan JS, Whittle MC, Johnson GL. The dynamic nature of the kinome. Biochem J. 2013 Feb 15;450(1):1-8. PMCID: PMC3808244 

Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res. 2012 Oct 1;18(19):5290-303. PMCID: PMC3715399

Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, Hoadley KA, Zhou B, Sharpless NE, Perou CM, Kim WY, Gomez SM, Chen X, Jin J, Frye SV, Earp HS, Graves LM, Johnson GL. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancerCell. 2012 Apr 13;149(2):307-21. PMCID: PMC3328787

Midland AA, Whittle MC, Duncan JS, Abell AN, Nakamura K, Zawistowski JS, Carey LA, Earp HS 3rd, Graves LM, Gomez SM, Johnson GL. Defining the expressed breast cancer kinome. Cell Res. 2012 Apr;22(4):620-3. PMCID: PMC3317564